Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $11

Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating on CytomX Therapeutics (NASDAQ: CTMX) and increased the price target from $6 to $11. This adjustment reflects a positive outlook for the company's performance in the market.